Dendritic cells (DCs) are bone marrow-derived mononuclear cells that play a central role in the initiation of immune responses. Because human lung DCs have been incompletely characterized, we enumerated and phenotyped mononuclear cell populations from excess lung tissue obtained at surgery. Myeloid DCs (MDCs) were identified as CD1c(+)CD11c(+)CD14(-)HLA-DR(+) cells and comprised approximately 2...

Objective. To determine the immunological predictors of renal graft rejection in early postoperative period. Methods. Three groups were formed out 197 recipients. The group PGF (n=101) was made up patients with satisfactory primary function. PGD (n = 82) included dysfunction without episodes rejection. RGR (n=14) consisted and On 7<sup>th</sup> day after transplantation kidney funct...

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy that is known to be derived from plasmacytoid dendritic cells which are characterized by expression of CD4, CD56, and more specific markers such as CD123. Here, the authors present three cases of BPDCN diagnosed in the past two years and address different available diagnostic modalities such as morpho...

sis of the CSF showed neoplastic cells with a frequency of 92.0% (Fig. 2C) and positivity for both CD56 and CD123 on immunocytochemical staining (Fig. 2D). He was diagnosed with leptomeningeal involvement of BPDCN. He was treated with intrathecal injections of high-dose cytarabine (40 mg) and methotrexate (15 mg) for 3 months, and he has been in complete remission for 4 months without evidence ...

Fig. 1. Bone marrow (BM) aspiration and biopsy findings in the first case. BM aspiration showed the presence of neoplastic cells (27.8%) with oval to round nuclei, prominent nucleoli, and abundant amount of bluish cytoplasm (A, Wright staining, ×1,000). The BM clot section also showed interstitial infiltration of neoplastic cells (B, hematoxylin and eosin staining, ×400) positive for CD4, CD56,...

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells Marco Ruella, David M Barrett, Saad S Kenderian, Olga Shestova, Ted J Hofmann, John Scholler, Simon F Lacey, Jan J Melenhorst, Farzana Nazimuddin, Jessica Perazzelli, David A Christian, Christopher A Hunter, David L Porter, Carl H...